Canakinumab (Anti-IL-1b)

製品コードA2446 純度：99%

Canakinumab (Anti-IL-1b) is a recombinant human anti-IL-1β monoclonal antibody targeting IL-1β and neutralizing IL-1β signaling. It can be used in treatment of disorders of autoimmune origin like familial mediterranean fever, mevalonate kinase deficiency, tumor necrosis factor receptor-associated periodic syndrome (TRAPS). MW :145.5 KD.

サイズ（液体）	価格(税別)	在庫状況
1mg	JPY 44500	国内在庫なし(納期7~10日)
1mg*5	JPY 146500	お問い合わせ
1mg*25	JPY 445500	お問い合わせ

代表番号: 045-509-1970\|電子メール：sales@selleck.co.jp よく尋ねられる質問

文献中Selleckの製品使用例（1）

質量管理及び製品安全説明書

現在のバッチを見る：純度： 99% タンパク質濃度： 6.921mg/ml 内毒素：＜1EU/mg

Interleukins阻害剤の選択性比較

生物活性

製品説明	Canakinumab (Anti-IL-1b) is a recombinant human anti-IL-1β monoclonal antibody targeting IL-1β and neutralizing IL-1β signaling. It can be used in treatment of disorders of autoimmune origin like familial mediterranean fever, mevalonate kinase deficiency, tumor necrosis factor receptor-associated periodic syndrome (TRAPS). MW :145.5 KD.

製品説明

CAS No.	914613-48-2
Molecular Weight	145.5 kDa
Formulation	100 mM Pro-Ac, 20mM Arg, pH5.0
Isotype	Human IgG1
Source	CHO
Storage (From the date of receipt)	Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles.
Shipping	Shipped under low temperature conditions
Purification	AKTA
Sterility	0.2 μM filtered

各種クローンの論文数比較

^*Selleckは、市場の主要なクローンを収集し、2024年9月までの文献での使用状況を調査しました。その結果、Selleckの選定クローンが最も広く使用されていることが示されました。

臨床試験

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT06691217	RECRUITING	Drug: CANAKINUMAB (ILARIS®)\|Drug: Saline (NaCl 0,9 %) (place	Vascular Inflammation; ASCVD; ASCVD Management	Massachusetts General Hospital	2026-03-24	PHASE2
NCT05641831	RECRUITING	Drug: Canakinumab\|Drug: Placebo Administration	Clonal Cytopenia of Undetermined Significance	Uma Borate	2023-02-06	PHASE2
NCT07138898	RECRUITING	Drug: Methotrexate\|Drug: Sulfasalazine\|Drug: Hydroxychloroqu	Rheumatic Disease	NYU Langone Health	2025-12-12	PHASE2
NCT04789681	RECRUITING	Drug: Canakinumab	Lung Carcinoma; Stage I Lung Cancer AJCC v8; Stage IA1 Lung Cancer AJCC v8; Stage IA2 Lung Cancer AJCC v8; Stage IA3 Lung Cancer AJCC v8; Stage IB Lung Cancer AJCC v8; Stage II Lung Cancer AJCC v8; Stage IIA Lung Cancer AJCC v8; Stage IIB Lung Cancer AJCC v8; Stage III Lung Cancer AJCC v8; Stage IIIA Lung Cancer AJCC v8; Stage IIIB Lung Cancer AJCC v8; Stage IIIC Lung Cancer AJCC v8	M.D. Anderson Cancer Center	2021-07-20	PHASE2
NCT05535738	ACTIVE_NOT_RECRUITING	Drug: Squaric Acid Dibutyl Ester\|Drug: Dupilumab\|Drug: Adali	Skin Inflammation; Allergic Contact Dermatitis	Wei-Che Ko	2022-11-15	PHASE2; PHASE3
NCT04239157	RECRUITING		Chronic Myelomonocytic Leukemia; Myelodysplastic Syndrome; Recurrent Chronic Myelomonocytic Leukemia; Recurrent Myelodysplastic Syndrome; Refractory Chronic Myelomonocytic Leukemia; Refractory Myelodysplastic Syndrome	M.D. Anderson Cancer Center	2020-08-25	PHASE2

(data from https://clinicaltrials.gov, updated on 2026-06-18)

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

* 必須